Serotonin excitation of facial motoneurons: receptor subtype characterization.

The receptor subtype(s) mediating the enhancement of facial motoneuron excitability by serotonin (5-HT) was evaluated by means of single-cell recording in vivo (in the anesthetized rat) and in vitro in brain slices. In vivo, microiontophoretic application of the broad-spectrum 5-HT1 agonist 5-carboxamidotryptamine (5-CT), the 5-HT2/5-HT1C agonist 1-[2,5-dimethoxy-4-methylphenyl]-2-aminopropane (DOM), but not the selective 5-HT1A agonist 8-OH-2[di-n-propylamino]tetralin (8-OH-DPAT), produced a 5-HT-like enhancement of facial motoneuron excitability. Intravenous administration of the 5-HT2/5-HT1C antagonists ritanserin and LY 53857 in vivo blocked the facilitatory effects of 5-HT and DOM, but not norepinephrine (NE). Similarly, in brain slices, bath application of ritanserin blocked the effects of 5-HT, DOM, and 5-CT, but not NE on facial motoneurons. Intracellular recordings showed that DOM induced a slow depolarization and an increase in evoked spikes, but these effects were of lesser magnitude and longer duration than those produced by 5-HT. Taken together, these results indicate a role for 5-HT2 and/or 5-HT1C but not 5-HT1A receptors in serotonergic enhancement of facial motoneuron excitability since 5-HT's effect was 1) at least partially mimicked by the selective 5-HT2/5-HT1C agonist DOM, 2) mimicked by the broad-spectrum 5-HT1 agonist 5-CT but not the selective 5-HT1A agonist 8-OH-DPAT, and 3) blocked by the 5-HT2/5-HT1C antagonists ritanserin and LY 53857.